Emergency Approach to Buprenorphine and Methadone in Pregnancy

Introduction: Opioid use disorder (OUD) during pregnancy presents substantial challenges for both maternal and foetal health, necessitating effective management strategies to mitigate adverse outcomes.Buprenorphine and methadone are the primary maintenance therapies used to stabilise opioid levels, reduce cravings, and manage withdrawal symptoms in pregnant women with OUD.Pharmacological profiles: This article provides an in-depth exploration of the emergency approach to these treatments, emphasising their importance in preventing the complications associated with opioid withdrawal and misuse during pregnancy.We detail the pharmacological profiles of buprenorphine and methadone, highlighting their benefits, especially in terms of reducing the severity and duration of neonatal abstinence syndrome (NAS).Emergency management protocols: The article outlines comprehensive protocols for the emergency management of pregnant women on these therapies, including initial assessment procedures, pain management strategies, and methods for addressing opioid withdrawal symptoms.Obstetric considerations: Special attention is given to the obstetric considerations during labour and delivery, emphasising the need for continuous foetal monitoring and careful planning to manage potential complications.Postpartum considerations: Postpartum considerations, such as the safety of breastfeeding while on Buprenorphine or Methadone, and strategies for managing NAS in new-borns, are thoroughly examined.